Recently Featured

The rare disease revolution: The state of play for CGTs in orphan diseases

September 30, 2026
Cell and gene therapies (CGTs) are transforming the landscape of rare diseases, offering unprecedented opportunities to address long-standing unmet medical needs. As the biopharmaceutical industry increasingly invests in these innovative therapies, the number of clinical trials and approvals for orphan diseases has surged, reflecting a growing recognition of their potential to change patient outcomes significantly.…

GSK Consolidates Influenza Vaccine Manufacturing, Shuttering German Site

September 30, 2026
GSK has announced the closure of its German flu vaccine manufacturing site as part of a strategic consolidation of its production capabilities. This decision is expected to impact hundreds of jobs, raising concerns among employees and stakeholders in the pharmaceutical sector. The consolidation reflects a broader trend within the industry, where companies are increasingly seeking…

Public Trust in Science: A Complex Challenge for the Pharma Sector

September 30, 2026
Recent discussions among leaders in private foundations reveal a growing concern about the decline of public trust in science, particularly within the pharmaceutical sector. Many professionals suggest that improved communication could bridge this trust gap, while others argue that the issue is too vast for simple solutions. This divergence highlights a critical challenge: the need…

The GOP’s $50 billion rural health fund is coming up short, hospital leaders say

September 30, 2026
WASHINGTON — Hospital leaders are expressing concerns that the GOP’s $50 billion rural health fund may not adequately address the pressing needs of rural healthcare facilities. This funding, which was proposed amidst plans to cut $1 trillion from Medicaid over the next decade, is seen as insufficient by many in the healthcare sector. The context…

Ongoing Cases